Kronish Ian M, Woodward Mark, Sergie Ziad, Ogedegbe Gbenga, Falzon Louise, Mann Devin M
Division of General Internal Medicine, Mount Sinai School of Medicine, New York, NY, USA.
Circulation. 2011 Apr 19;123(15):1611-21. doi: 10.1161/CIRCULATIONAHA.110.983874. Epub 2011 Apr 4.
Observational studies suggest that there are differences in adherence to antihypertensive medications in different classes. Our objective was to quantify the association between antihypertensive drug class and adherence in clinical settings.
Studies were identified through a systematic search of English-language articles published from the inception of computerized databases until February 1, 2009. Studies were included if they measured adherence to antihypertensives using medication refill data and contained sufficient data to calculate a measure of relative risk of adherence and its variance. An inverse-variance-weighted random-effects model was used to pool results. Hazard ratios (HRs) and odds ratios were pooled separately, and HRs were selected as the primary outcome. Seventeen studies met inclusion criteria. The pooled mean adherence by drug class ranged from 28% for β-blockers to 65% for angiotensin II receptor blockers. There was better adherence to angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors (HR, 1.33; 95% confidence interval, 1.13 to 1.57), calcium channel blockers (HR, 1.57; 95% confidence interval, 1.38 to 1.79), diuretics (HR, 1.95; 95% confidence interval, 1.73 to 2.20), and β-blockers (HR, 2.09; 95% confidence interval, 1.14 to 3.85). Conversely, there was lower adherence to diuretics compared with the other drug classes. The same pattern was present when studies that used odds ratios were pooled. After publication bias was accounted for, there were no longer significant differences in adherence between angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors or between diuretics and β-blockers.
In clinical settings, there are important differences in adherence to antihypertensives in separate classes, with lowest adherence to diuretics and β-blockers and highest adherence to angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors. However, adherence was suboptimal regardless of drug class.
观察性研究表明,不同类别抗高血压药物的依从性存在差异。我们的目标是量化临床环境中抗高血压药物类别与依从性之间的关联。
通过系统检索从计算机化数据库建立之初至2009年2月1日发表的英文文章来确定研究。如果研究使用药物 refill 数据测量抗高血压药物的依从性,并包含足够的数据来计算依从性相对风险及其方差的测量值,则纳入研究。采用逆方差加权随机效应模型汇总结果。风险比(HRs)和比值比分别进行汇总,并选择HRs作为主要结果。17项研究符合纳入标准。各药物类别的合并平均依从性范围为β受体阻滞剂的28%至血管紧张素II受体阻滞剂的65%。与血管紧张素转换酶抑制剂相比,血管紧张素II受体阻滞剂的依从性更好(HR,1.33;95%置信区间,1.13至1.57),钙通道阻滞剂(HR,1.57;95%置信区间,1.38至1.79),利尿剂(HR,1.95;95%置信区间,1.73至2.20)和β受体阻滞剂(HR,2.09;95%置信区间,1.14至3.85)。相反,与其他药物类别相比,利尿剂的依从性较低。汇总使用比值比的研究时也出现了相同的模式。在考虑发表偏倚后,血管紧张素II受体阻滞剂与血管紧张素转换酶抑制剂之间或利尿剂与β受体阻滞剂之间的依从性不再存在显著差异。
在临床环境中,不同类别抗高血压药物的依从性存在重要差异,利尿剂和β受体阻滞剂的依从性最低,血管紧张素II受体阻滞剂和血管紧张素转换酶抑制剂的依从性最高。然而,无论药物类别如何,依从性都不理想。